Edinburgh Breakthrough Breast Cancer Research Unit, Endocrine Cancer Research Group, Western General Hospital, Edinburgh, UK.
Mol Diagn Ther. 2009 Dec 1;13(6):359-65. doi: 10.1007/BF03256341.
Our understanding of the human epidermal growth factor receptor (HER) family of proteins has increased over the last few decades. It is clear from the vast assortment of research that has been and is currently being carried out that there is still a lot to be learned. HER dimerization is known to activate various downstream pathways that have an effect on treatment and therapy for breast cancer. HER dimerization acts as a mechanism not only for amplifying the signal pathway but also for signal diversification. There is clear evidence that molecular subtypes of cancer respond differently to different therapeutic options, which challenges the 'one size fits all' approach to chemotherapy in cancer. Here, we review the methods by which HER dimerization can be explored and the potential that this has in the treatment of breast cancer.
在过去的几十年里,我们对人类表皮生长因子受体(HER)家族蛋白的理解有了很大的提高。从已经进行和正在进行的大量研究中可以清楚地看出,还有很多需要学习。HER 二聚化被认为可以激活各种下游通路,这些通路会对乳腺癌的治疗产生影响。HER 二聚化不仅作为一种信号通路放大的机制,也作为一种信号多样化的机制。有明确的证据表明,不同的癌症分子亚型对不同的治疗选择有不同的反应,这对癌症的“一刀切”化疗方法提出了挑战。在这里,我们回顾了探索 HER 二聚化的方法及其在乳腺癌治疗中的潜力。